Search Results - "Watson, Evangeline"

Targeting a neoantigen derived from a common TP53 mutation by Hsiue, Emily Han-Chung, Wright, Katharine M, Douglass, Jacqueline, Hwang, Michael S, Mog, Brian J, Pearlman, Alexander H, Paul, Suman, DiNapoli, Sarah R, Konig, Maximilian F, Wang, Qing, Schaefer, Annika, Miller, Michelle S, Skora, Andrew D, Azurmendi, P Aitana, Murphy, Michael B, Liu, Qiang, Watson, Evangeline, Li, Yana, Pardoll, Drew M, Bettegowda, Chetan, Papadopoulos, Nickolas, Kinzler, Kenneth W, Vogelstein, Bert, Gabelli, Sandra B, Zhou, Shibin

“…(tumor protein p53) is the most commonly mutated cancer driver gene, but drugs that target mutant tumor suppressor genes, such as , are not yet available…”
Get full text

Bispecific antibodies targeting mutant RAS neoantigens by Douglass, Jacqueline, Hsiue, Emily Han-Chung, Mog, Brian J, Hwang, Michael S, DiNapoli, Sarah R, Pearlman, Alexander H, Miller, Michelle S, Wright, Katharine M, Azurmendi, P Aitana, Wang, Qing, Paul, Suman, Schaefer, Annika, Skora, Andrew D, Molin, Marco Dal, Konig, Maximilian F, Liu, Qiang, Watson, Evangeline, Li, Yana, Murphy, Michael B, Pardoll, Drew M, Bettegowda, Chetan, Papadopoulos, Nickolas, Gabelli, Sandra B, Kinzler, Kenneth W, Vogelstein, Bert, Zhou, Shibin

“…Mutations in the oncogenes occur in multiple cancers, and ways to target these mutations has been the subject of intense research for decades. Most of these…”
Get more information

TRBC1-targeting antibody–drug conjugates for the treatment of T cell cancers by Nichakawade, Tushar D., Ge, Jiaxin, Mog, Brian J., Lee, Bum Seok, Pearlman, Alexander H., Hwang, Michael S., DiNapoli, Sarah R., Wyhs, Nicolas, Marcou, Nikita, Glavaris, Stephanie, Konig, Maximilian F., Gabelli, Sandra B., Watson, Evangeline, Sterling, Cole, Wagner-Johnston, Nina, Rozati, Sima, Swinnen, Lode, Fuchs, Ephraim, Pardoll, Drew M., Gabrielson, Kathy, Papadopoulos, Nickolas, Bettegowda, Chetan, Kinzler, Kenneth W., Zhou, Shibin, Sur, Surojit, Vogelstein, Bert, Paul, Suman

“…Antibody and chimeric antigen receptor (CAR) T cell-mediated targeted therapies have improved survival in patients with solid and haematologic malignancies 1 –…”
Get full text

Preclinical studies show that Co-STARs combine the advantages of chimeric antigen and T cell receptors for the treatment of tumors with low antigen densities by Mog, Brian J, Marcou, Nikita, DiNapoli, Sarah R, Pearlman, Alexander H, Nichakawade, Tushar D, Hwang, Michael S, Douglass, Jacqueline, Hsiue, Emily Han-Chung, Glavaris, Stephanie, Wright, Katharine M, Konig, Maximilian F, Paul, Suman, Wyhs, Nicolas, Ge, Jiaxin, Miller, Michelle S, Azurmendi, P, Watson, Evangeline, Pardoll, Drew M, Gabelli, Sandra B, Bettegowda, Chetan, Papadopoulos, Nickolas, Kinzler, Kenneth W, Vogelstein, Bert, Zhou, Shibin

“…Two types of engineered T cells have been successfully used to treat patients with cancer, one with an antigen recognition domain derived from antibodies…”
Get more information

Abstract 2082: Identification of nonsense-mediated decay inhibitors that alter the tumor immune landscape by Cook, Ashley L., Sur, ojit, Dobbyn, Laura, Watson, Evangeline, Cohen, Joshua D., Ptak, Blair, Lee, Bum Seok, Paul, Suman, Hsiue, Emily, Popoli, Maria, Vogelstein, Bert, Papadopoulos, Nickolas, Bettegowda, Chetan, Gabrielson, Kathy, Zhou, Shibin, Kinzler, Kenneth, Wyhs, Nicolas

“…Despite exciting developments in cancer immunotherapy, its broad application is limited by the paucity of targetable antigens on the tumor cell surface. As an…”
Get full text

Abstract LB095: Hybrid TCR-CAR design surpasses conventional CARs and patient-derived TCRs in targeting an ultra-low-density neoantigen by Mog, Brian J., DiNapoli, Sarah R., Hwang, Michael S., Nichakawade, Tushar D., Douglass, Jacqueline, Hsiue, Emily Han-Chung, Wright, Katharine M., Pearlman, Alexander H., Konig, Maximilian F., Paul, Suman, Wyhs, Nicolas, Marcou, Nikita, Glavaris, Stephanie, Ge, Jiaxin, Miller, Michelle S., Azurmendi, P. Aitana, Watson, Evangeline, Pardoll, Drew M., Gabelli, Sandra B., Bettegowda, Chetan, Papadopoulos, Nickolas, Kinzler, Kenneth W., Vogelstein, Bert, Zhou, Shibin

“…Mutation-associated neoantigens (MANAs) are exquisitely cancer-specific therapeutic targets. However, MANAs are present at ultra-low densities on the cancer…”
Get full text